Intranasal ACCS and AMP Cells for Ocular Trauma Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular contusion, blunt eye injuries, and traumatic optic neuropathy are limited in their ability to repair cellular architecture and promote regeneration, with no effective methods to restore cellular structure or function in traumatized eye tissues, and existing neuroprotective therapies have failed to translate from animal models to human clinical trials.
Innovation Solution
Administration of Amnion-derived Cellular Cytokine Solution (ACCS) and Amnion-derived Multipotent Progenitor (AMP) cells via intranasal route, utilizing immediate-release, targeted-release, and sustained-release compositions to deliver cytokines and cellular factors that support healing and regeneration, including topical and intraocular administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mechanical repair and lens replacement are used for ocular injuries, then structural damage can be addressed, but cellular architecture repair and tissue regeneration cannot be achieved
Solution Approach 1:
The patent uses amnion-derived multipotent progenitor cells as intermediary agents that mediate between the injured ocular tissue and the regeneration process. These cells serve as biological mediators that can differentiate into various ocular cell types and secrete trophic factors, bridging the gap between mechanical repair and cellular regeneration by facilitating tissue reconstruction at the cellular level.
Solution Approach 2:
The patent changes the therapeutic parameter from mechanical intervention to biological intervention by introducing living cells and their secreted factors. This parameter change enables the system to transition from merely restoring structure to actively promoting cellular proliferation, differentiation, and tissue regeneration, thereby achieving both structural repair and cellular reconstruction.
2Reliability
If single-agent neuroprotective therapies are used in animal models, then neuronal damage can be reduced, but translation to human clinical trials has failed
Solution Approach 1:
The patent merges multiple therapeutic mechanisms into a single cell-based therapy. The amnion-derived multipotent progenitor cells simultaneously provide neuroprotection through multiple pathways: direct cell replacement, secretion of multiple trophic factors (BDNF, GDNF, NGF), anti-inflammatory effects, and promotion of axonal regeneration. This combination of mechanisms within one therapeutic agent improves clinical translatability by addressing multiple aspects of neuronal injury recovery concurrently.
Solution Approach 2:
The patent creates a composite biological therapy consisting of multipotent progenitor cells that produce and secrete multiple bioactive molecules. This composite approach combines cellular therapy with pharmacological therapy (trophic factors) in a single treatment, creating a synergistic effect that enhances neuroprotection and improves the likelihood of clinical success compared to single-agent therapies.
3Speed
If immediate-release ACCS compositions are used, then rapid therapeutic effect is achieved, but sustained regeneration support is limited
Solution Approach 1:
The patent applies preliminary action by administering ACCS immediately after ocular injury to rapidly reduce inflammation and prevent secondary damage. This initial rapid intervention creates a favorable environment for subsequent regeneration processes, addressing the acute phase needs first before sustained regeneration support becomes the primary focus.
Solution Approach 2:
The patent ensures continuity of useful action by combining immediate-release ACCS with sustained-release formulations and/or repeated administrations. This continuous therapeutic presence maintains anti-inflammatory effects and promotes regeneration over an extended period, bridging the gap between acute injury response and long-term tissue recovery.
4Adaptability or versatility
If multiple delivery routes are used for ACCS, then therapeutic coverage is improved, but administration complexity increases
Solution Approach 1:
The patent inverts the conventional approach by using the intranasal route (an unconventional route for ocular therapy) to deliver therapeutic agents to the optic nerve and ocular tissues. This inversion leverages the olfactory-trigeminal neural pathway and nasociliary artery connections to achieve ocular delivery, simplifying administration while expanding therapeutic coverage to include the optic nerve and retrobulbar structures.
Data Source
AI summary
The invention is directed to methods for treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve. The invention is further directed to treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve by administering to a subject suffering from such conditions Amnion-derived Cellular Cytokine Solution (ACCS), including immediate-release, targeted-release, and sustained-release (SR) ACCS compositions (referred to herein as “SR-ACCS” compositions) and/or Amnion-derived Multipotent Progenitor (AMP) cell compositions. Such administration includes intranasal administration of ACCS and/or AMP cells.